Canid, a New York-based provider of an end-to-end platform for vaccine automation and management, raised $1.5M in funding.
The round was led by SeedtoB Capital, with participation from FJ Labs, Alumni Ventures, I2BF and MKT1.
The company intends to use the funds to expand its geographic presence to 10 new states across the U.S. and add new tools to manage vaccine patient populations.
Led by Pedro Sanchez de Lozada, Founder and CEO, Canid provides an end-to-end vaccine workflow automation and management solution, allowing practices to manage the purchasing, delivery, and record management of vaccines. Its suite of tools offers practices a unified way to engage patients and close care gaps, while minimizing provider burnout and delivering higher-quality care, to empower clinicians to deliver care and drive improvements in public health.
FinSMEs
22/09/2023